Mar 30 2007
A selection of our pipework has been specified for a new state-of-the-art clinical imaging centre at Imperial College London.
Located on the former Burlington Danes school site, this new centre of excellence adjoins Hammersmith Hospital, which is already well-known as a leading imaging facility, home to many world experts in imaging technology.
Contractors, Haden Young, specified our Vulcathene chemical drainage system in sizes ranging from 38mm to 152mm, to run throughout the laboratories.
A spokesperson for Haden Young commented: “The Vulcathene system offered practical solutions for the Burlington Danes project that not only met the essential requirements, but also offered ease of installation, reliability and manoeuvrability on site.
“The Vulcathene system was used primarily because it is a completely corrosion resistant plumbing system, which is necessary as there will be a variety of substances that the pipework will need to cope with on a daily basis.”
Vulcathene is a mechanical system featuring a comprehensive range of pipes and fittings from 38mm up to 152mm. The system also encompasses laboratory bench items such as waste, sinks and drip cups, anti-siphon traps and expansion joints.
Consulting engineers, Norman, Disney and Young, specified Durapipe ABS pressure pipework in sizes ranging from 32mm to 40mm for the purified water system and Friatherm pipework in sizes from 16mm to 110mm for general water services.
A spokesperson for Consultant Engineer Norman, Disney & Young, commented: “We specified Friatherm as a hot and cold pipework system because of its speed of installation and long-term performance benefits which culminated in significant advantages when compared to alternative pipework systems. Furthermore, ABS was chosen specifically for its durability and suitability for use with purified water systems.”
Both Friatherm and ABS pipework boast a 50 year life expectancy and are WRAS (Water Regulations Advisory Scheme) approved.
The Burlington Danes development at Imperial College London is due for completion later in the year, when long term research on cancer, stroke, neurological diseases and psychiatric diseases will begin.